Kura Oncology Inc. (KURA)

19.4 0 (0%)

IEX Real-Time Price

August 16, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 19.4

Price Open 19.25

Volume: 135,904

Avg Volume: 234,891

Market Cap: 736.72M

P/E Ratio -11.69

52 Wk Range 5.9-24.025



KURA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
37.94M
2.29M
9.12
6.04%

2018-07-13
32.82M
2.33M
5.68
7.10%

2018-06-29
32.82M
2.26M
5.95
6.90%

2018-06-15
32.82M
1.91M
7.20
5.83%




KURA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-21
Q1 2018
N/A
-0.33 (4)
0.00
0.00

2018-05-08
Q1 2018
AMC
-0.33 (4)
-0.46
-0.13

2018-03-13
Q4 2017
N/A
-0.36 (4)
-0.37
-0.03

2018-03-12
Q4 2017
AMC
-0.34 (4)
-0.37
-0.03

News

Kura Oncology's (KURA) CEO Troy Wilson on Q2 2018 Results - Earnings Call Transcript (2018-08-06 23:03 SeekingAlpha)

Kura Oncology (KURA) Q2 2018 Results Earnings Conference Call August 6, 2018, 04:30 PM ET Executives Pete De Spain - Vice President, Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Antonio Gualberto - Head, Development and Chief…

 


Statistics

Shares Outstanding: 37.98M

Top 15 Institution Percent: 66.50

Price To Sales: N/A

Price To Book: 6.52

Revenue: N/A

Gross Profit: N/A

Cash: 100.81M

Debt: 7.04M

Return On Assets: -53.29

Return On Equity: -63.35

Profit Margin: N/A

Price History

Beta: 4.26

50-day Moving Avg: 19.21

200-day Moving Avg: 17.77

YTD Change: 25.57

5-day Change: 1.57

1-month Change: -2.76

3-month Change: 12.79

6-month Change: -14.73

1-year Change: 198.46

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Kura Oncology Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.kuraoncology.com

Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.